Core Viewpoint - The introduction of radioligand therapy using Lutetium-177 for advanced prostate cancer patients marks a significant advancement in treatment options in East China, providing a new hope for patients with drug-resistant conditions [1][2]. Group 1: Treatment Overview - Radioligand therapy is described as an innovative method that precisely targets tumor cells and releases radiation, likened to a "biological missile" in the fight against cancer [2]. - The therapy consists of two main components: a targeting ligand that identifies specific markers on prostate cancer cells (PSMA) and the radioactive isotope Lutetium-177 that emits beta radiation [2]. - The therapy's precision is highlighted by the fact that Lutetium-177's beta radiation can only penetrate about 2 millimeters into soft tissue, allowing for concentrated radiation delivery to tumor cells while minimizing damage to surrounding healthy tissue [2]. Group 2: Treatment Process - A key advantage of this therapy is the "integrated diagnosis and treatment" approach, where patients must undergo a PSMA PET/CT scan to confirm eligibility for the treatment, ensuring its precision and effectiveness [3]. - The treatment consists of 4-6 cycles, with evaluations of the patient's overall condition conducted after the 2nd and 4th cycles to determine the continuation of therapy [3].